Laboratory Products
Multiplexing Detection Kits in Development
Dec 19 2008
The new bead-based multiplexed assays will give pharma and biotech researchers a direct comparative measurement of multiple protein expression patterns without the need for extrapolation among results from independent assays. This new powerful capability will allow
researchers to obtain an overall picture of the way a particular stimulus, such as a new drug candidate, affects multiple proteins simultaneously. Consequently a more accurate prediction of the
overall physiological effects of the stimulus, such as the response to a drug candidate, is achievable.
In addition, the new multiplexed assays will also help researchers identify differences in proteins or protein levels between healthy and disease states, providing insight into disease cause and progression.
Based on innovative fluorescence technology, the new bead-based offer higher sensitivity and a greater linear range of detection than assays that employ enzymatic or colorimetric readouts. The first bead-based kits to hit the market will target cytokines and chemokines. They will be sold as individual kits. In addition, Guava Technologies will offer several pre-packaged multiplex kits. The kits will be compatible with Guava® Flow Cytometers, such as the Guava EasyCyte⢠Plus System,
running Guava® Simplicity Software, which, like the detection kits, is in the final development stage and will be available within several months.
Digital Edition
Lab Asia 29.6 Dec
December 2022
In This Edition Chromatography - Optimising Viral Vector Purification Strategies with Multimodal Chromatography - Key UHPLC Characteristics Required for High throughput LC-MS - New Low Volu...
View all digital editions
Events
Feb 06 2023 Dubai, UAE
Feb 14 2023 Cologne, Germany
Feb 22 2023 Amsterdam, Netherlands
Salon International des Laboratories Lab Expo
Feb 22 2023 Tunis, Tunisia
Feb 25 2023 San Diego, CA, USA